ArticlePloS one2025
Real-world safety profile of live attenuated Japanese encephalitis vaccine before and after the vaccine administration law.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeLive attenuated Japanese encephalitis vaccine (JEV-L) was included in the Expanded program on immunization on Immunization (EPI) in 2008 and has had a satisfactory effectiveness and safety profile in protecting children from JE virus infection. This study was designed to evaluate the surveillance sensitivity and changes over time of adverse event following immunization (AEFI) reports related to JEV-L based on the national AEFI surveillance system(NAEFISS) data before and after the introduction of vaccine administration law (LAW) from 2014 to2023 in Huzhou City.
methodsAEFI data were collected from NAEFISS from 2014 to 2023 and included age, AEFI and diagnostic categories. AEFI incidence rates are calculated/10,000 vaccine doses and a reporting odds ratio -1.96 standard error (ROR-1.96SE) >1 defined a positive signal between AEFI and vaccine. We categorized the time interval into the pre-LAW period (2014-2019) and post-LAW period (2020-2023) to demonstrate the impact of LAW on the surveillance of AEFI.
resultsThe NAEFISS collected 225 AEFI reports after administering 599,223 doses of JEV-L, with a AEFI reported rate of 3.75/10,000 doses. Overall AEFI reported rates increased over time with a drop in 2020 (P < 0.001, χ2 for trend). The reported rate of AEFI in post-LAW period was higher than that in the pre-LAW period (P < 0.001), accounted for increases in fever, local redness and local induration. However, the reported rate of urticaria decreased significantly in post-LAW period(P = 0.043). This study found a positive signal association between JEV-L immunization and fever in the pre- (1.394) and post-LAW period(2.833) and a signal for urticaria in the pre-LAW period (2.098). There were only 2 severe reactions reported: thrombocytopenia and epilepsy.
conclusionsThe implementation of the LAW significantly enhanced the surveillance capacity and sensitivity for AEFIs associated with JEV-L. This study did not find any new/unexpected safety concern in the post-LAW period. Severe reactions remain rare despite the greatly improved sensitivity of surveillance, indicating that the vaccine was comparatively safe. However, continuous epidemiological investigation are needed to systematically assessment the data provided by NAEFISS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.